2. Search Result
Search Result
Results for "

retinal degeneration

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Inhibitory Antibodies

4

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116098
    Anecortave desacetate

    AL-4940

    		 Biochemical Assay Reagents Cancer
    Anecortave desacetate (AL-4940) is an angiogenesis inhibitor. Anecortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors .
    Anecortave desacetate
  • HY-124717
    YC-001

    		Endogenous Metabolite Others
    YC-001 is an inverse agonist and antagonist of rod opsin. YC-001 reversibly binds rod opsin and stabilizes the rod opsin structure. YC-001 protects mice from bright light-induced retinal degeneration. YC-001 has the potential for the research of retinal degeneration .
    YC-001
  • HY-P99576
    Tarcocimab

    OG1953

    		 VEGFR Others
    Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
    Tarcocimab
  • HY-140739
    DSPE-PEG2000-Maleimide
    2 Publications Verification

    		 Liposome Neurological Disease Cancer
    DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .
    DSPE-PEG2000-Maleimide
  • HY-101446
    HIOC

    		Trk Receptor ERK Apoptosis Neurological Disease
    HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration .
    HIOC
  • HY-P99116
    Faricimab

    RG7716

    		 VEGFR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
    Faricimab
  • HY-140739A
    DSPE-PEG2000-Maleimide free acid

    		Liposome Neurological Disease Cancer
    DSPE-PEG2000-Maleimide free acid is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide free acid utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide free acid covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide free acid can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .
    DSPE-PEG2000-Maleimide free acid
  • HY-109869
    Photoregulin1

    		Orphan Receptor Others
    Photoregulin1 is a compound with the potential to inhibit retinitis pigmentosa that modulates gene expression in retinal cells and slows the degeneration of photoreceptors in a mouse model.
    Photoregulin1
  • HY-113127
    L-Tryptophanamide

    		Apoptosis Others
    L-Tryptophanamide is a compound discovered in wet age-related macular degeneration research, which has activities related to affecting retinal cell proliferation, apoptosis, necrosis and angiogenesis. In in vitro experiments, L-Tryptophanamide affects the proliferation, apoptosis and necrosis of human retinal pigment epithelial cells, and promotes tube formation and migration of human retinal endothelial cells.
    L-Tryptophanamide
  • HY-136234
    9-cis-β-Carotene

    		Endogenous Metabolite Others
    9-cis-β-Carotene, a precursor of retinal, is cleaved by beta-carotene oxygenase 1 (BCMO1) to produce 9-cis-retinal. 9-cis-β-Carotene inhibits photoreceptor degeneration and restores retinal function in vivo. 9-cis-β-Carotene has the potential for the study of congenital stationary night blindness and fundus albipunctatus .
    9-cis-β-Carotene
  • HY-172232
    STG-001

    		Lipocalin Family Neurological Disease
    STG-001 is a retinol binding protein 4 (RBP4) antagonist. STG-001 inhibits RBP4 to reduce the synthesis of retinal and diretinol, thereby preventing photoreceptor degeneration. STG-001 can be used in the study of sexually precocious nephropathy (STGD) .
    STG-001
  • HY-N7270
    Apigenin-7-diglucuronide

    		Others Inflammation/Immunology
    Apigenin-7-diglucuronide is a flavonoid glycoside and is present in an assortment of medicinal plants with anti-inflammatory or ant-oxidant activities. Apigenin-7-diglucuronide protects retinas against bright light-induced photoreceptor degeneration through the inhibition of retinal oxidative stress and inflammation .
    Apigenin-7-diglucuronide
  • HY-N11499
    Myricetin 3-O-α-L-arabinopyranoside

    		Bacterial Infection Inflammation/Immunology
    Myricetin 3-O-α-L-arabinopyranoside is a quercetin derivative and plant flavonoid with antioxidant, antibacterial and antiurease effects. Myricetin 3-O-α-L-arabinopyranoside inhibits A2E photooxidation-induced RPE cell death. Myricetin 3-O-α-L-arabinopyranoside is protective against retinal degeneration and protects against blue light (BL)-induced damage in RPE cells and mouse models .
    Myricetin 3-O-α-L-arabinopyranoside
  • HY-110195
    Smurf1-IN-A01
    1 Publications Verification

    A01

    		 HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR Others Cancer
    Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .
    Smurf1-IN-A01
  • HY-162904
    BPU17

    		Mitochondrial Metabolism Cardiovascular Disease
    BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .
    BPU17
  • HY-122129
    Dotriaconta-14,17,20,23,26,29-hexaenoic acid

    		Endogenous Metabolite Metabolic Disease
    Very long chain polyunsaturated fatty acids (VLCPUFA) are present in retina, sperm, and brain. Though little is known of their biosynthesis or functional roles in these tissues, recent studies using the elongation of very long-chain FA-4 protein suggest a unique role for VLCPUFA in retinal development and macular degeneration. Dotriaconta-14,17,20,23,26,29-hexaenoic acid is a C32:6 VLCPUFA whose specific biological actions are largely unknown, but are thought to involve normal photoreceptor cell function in the retina.
    Dotriaconta-14,17,20,23,26,29-hexaenoic acid
  • HY-122129S
    Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d6

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d6 is deuterium labeled Dotriaconta-14,17,20,23,26,29-hexaenoic acid. Very long chain polyunsaturated fatty acids (VLCPUFA) are present in retina, sperm, and brain. Though little is known of their biosynthesis or functional roles in these tissues, recent studies using the elongation of very long-chain FA-4 protein suggest a unique role for VLCPUFA in retinal development and macular degeneration. Dotriaconta-14,17,20,23,26,29-hexaenoic acid is a C32:6 VLCPUFA whose specific biological actions are largely unknown, but are thought to involve normal photoreceptor cell function in the retina .
    Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d6
  • HY-107543
    8-pCPT-2′-O-Me-cAMP sodium
    1 Publications Verification

    8-CPT-2'-O-Me-cAMP sodium

    		 Ras Cardiovascular Disease
    8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP) sodium, an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP sodium activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50 >10 μM). 8-pCPT-2′-O-Me-cAMP sodium stimulates Epac-mediated Ca 2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP sodium is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP sodium enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .
    8-pCPT-2′-O-Me-cAMP sodium
  • HY-116312
    8-pCPT-2′-O-Me-cAMP

    8-CPT-2'-O-Me-cAMP

    		 Ras Cardiovascular Disease
    8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP), an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50 >10 μM). 8-pCPT-2′-O-Me-cAMP stimulates Epac-mediated Ca 2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .
    8-pCPT-2′-O-Me-cAMP
  • HY-14608R
    L-Glutamic acid (Standard)

    		Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC50 & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus .
    L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma .
    In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice .
    L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .
    L-Glutamic acid (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: